Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry
Final published version, 1.03 MB, PDF document
Objective Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019.
Methods This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits.
Results A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naive. Compared to previously treated patients, treatment-naive patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naive versus previously treated patients experienced a relapse during the follow-up (p
Conclusions Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity.
Original language | English |
---|---|
Article number | 0250820 |
Journal | PLoS ONE |
Volume | 16 |
Issue number | 5 |
Number of pages | 16 |
ISSN | 1932-6203 |
DOIs | |
Publication status | Published - 2021 |
- DISEASE-MODIFYING THERAPIES, ORAL TERIFLUNOMIDE, RELAPSING FORMS, TREATMENT DECISIONS, REPORTED OUTCOMES, DOUBLE-BLIND, TRIAL, TOWER, AGE
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 274060313